secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bioventus Inc. (BVS)
CIK:        0001665988
Form:       8-K
Filed at:   2026-08-05T11:40:11+00:00
Accession:  0001665988-26-000041
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bioventus Q2 revenue $153.2M (+4%), GAAP EPS $0.47; initiates strategic alternatives review
--------------------------------------------------------------------------------

- Q2 revenue $153.2M (+4% YoY); GAAP EPS $0.47 vs $0.11; non-GAAP EPS $0.22 vs $0.21.
- Pain Treatments revenue $81.7M (+11.5%); Surgical Solutions $50.4M (-4.5%); Restorative Therapies $21.1M (-2.4%).
- Reaffirmed FY2026 guidance: net sales $600-610M, adjusted EPS $0.75-0.79, cash from ops $84-89M.
- Board formed independent committee to evaluate strategic alternatives including sale, after unsolicited proposal.
- Made $20M discretionary principal prepayment on term loan during Q2.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1665988/000166598826000041/0001665988-26-000041-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1665988/000166598826000041/bvs-20260805.htm
  HTML page:      https://secwatch.observer/filing/0001665988-26-000041

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer